Medical Care
Global Oncolytic Virus Manufacturing and Development Services Market Outlook, In‑Depth Analysis & Forecast to 2031
- Oct 16, 25
- ID: 552455
- Pages: 143
- Figures: 144
- Views: 2
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Oncolytic Virus Manufacturing and Development Services market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Recipharm (Vibalogics)
IDT Biologika
FUJIFILM Diosynth Biotechnologies
Exothera
Lonza
Creative Biolabs
Takara Bio
Libentech
ABL
Nabios
Halix
Obio Technology
Porton Advanced
WuXi ATU
Genevoyager
Segment by Type
Oncolytic Herpes Simplex Virus
Oncolytic Adenovirus
Oncolytic Vaccinia Virus
Others
Segment by Application
R&D
Biopharmaceutical Manufacturers
Others
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Oncolytic Virus Manufacturing and Development Services study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Oncolytic Virus Manufacturing and Development Services market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Recipharm (Vibalogics)
IDT Biologika
FUJIFILM Diosynth Biotechnologies
Exothera
Lonza
Creative Biolabs
Takara Bio
Libentech
ABL
Nabios
Halix
Obio Technology
Porton Advanced
WuXi ATU
Genevoyager
Segment by Type
Oncolytic Herpes Simplex Virus
Oncolytic Adenovirus
Oncolytic Vaccinia Virus
Others
Segment by Application
R&D
Biopharmaceutical Manufacturers
Others
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Oncolytic Virus Manufacturing and Development Services study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Oncolytic Virus Manufacturing and Development Services: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Oncolytic Virus Manufacturing and Development Services Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Oncolytic Herpes Simplex Virus
1.2.3 Oncolytic Adenovirus
1.2.4 Oncolytic Vaccinia Virus
1.2.5 Others
1.3 Market Segmentation by Application
1.3.1 Global Oncolytic Virus Manufacturing and Development Services Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 R&D
1.3.3 Biopharmaceutical Manufacturers
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Oncolytic Virus Manufacturing and Development Services Revenue Estimates and Forecasts 2020-2031
2.2 Global Oncolytic Virus Manufacturing and Development Services Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Oncolytic Virus Manufacturing and Development Services Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Oncolytic Virus Manufacturing and Development Services Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Oncolytic Herpes Simplex Virus Market Size by Players
3.3.2 Oncolytic Adenovirus Market Size by Players
3.3.3 Oncolytic Vaccinia Virus Market Size by Players
3.3.4 Others Market Size by Players
3.4 Global Oncolytic Virus Manufacturing and Development Services Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Oncolytic Virus Manufacturing and Development Services Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Oncolytic Virus Manufacturing and Development Services Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Oncolytic Virus Manufacturing and Development Services Market Size by Type (2020-2031)
6.4 North America Oncolytic Virus Manufacturing and Development Services Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Oncolytic Virus Manufacturing and Development Services Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Oncolytic Virus Manufacturing and Development Services Market Size by Type (2020-2031)
7.4 Europe Oncolytic Virus Manufacturing and Development Services Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Oncolytic Virus Manufacturing and Development Services Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Oncolytic Virus Manufacturing and Development Services Market Size by Type (2020-2031)
8.4 Asia-Pacific Oncolytic Virus Manufacturing and Development Services Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Oncolytic Virus Manufacturing and Development Services Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Oncolytic Virus Manufacturing and Development Services Market Size by Type (2020-2031)
9.4 Central and South America Oncolytic Virus Manufacturing and Development Services Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Oncolytic Virus Manufacturing and Development Services Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Oncolytic Virus Manufacturing and Development Services Market Size by Type (2020-2031)
10.4 Middle East and Africa Oncolytic Virus Manufacturing and Development Services Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Oncolytic Virus Manufacturing and Development Services Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Recipharm (Vibalogics)
11.1.1 Recipharm (Vibalogics) Corporation Information
11.1.2 Recipharm (Vibalogics) Business Overview
11.1.3 Recipharm (Vibalogics) Oncolytic Virus Manufacturing and Development Services Product Features and Attributes
11.1.4 Recipharm (Vibalogics) Oncolytic Virus Manufacturing and Development Services Revenue and Gross Margin (2020-2025)
11.1.5 Recipharm (Vibalogics) Oncolytic Virus Manufacturing and Development Services Revenue by Product in 2024
11.1.6 Recipharm (Vibalogics) Oncolytic Virus Manufacturing and Development Services Revenue by Application in 2024
11.1.7 Recipharm (Vibalogics) Oncolytic Virus Manufacturing and Development Services Revenue by Geographic Area in 2024
11.1.8 Recipharm (Vibalogics) Oncolytic Virus Manufacturing and Development Services SWOT Analysis
11.1.9 Recipharm (Vibalogics) Recent Developments
11.2 IDT Biologika
11.2.1 IDT Biologika Corporation Information
11.2.2 IDT Biologika Business Overview
11.2.3 IDT Biologika Oncolytic Virus Manufacturing and Development Services Product Features and Attributes
11.2.4 IDT Biologika Oncolytic Virus Manufacturing and Development Services Revenue and Gross Margin (2020-2025)
11.2.5 IDT Biologika Oncolytic Virus Manufacturing and Development Services Revenue by Product in 2024
11.2.6 IDT Biologika Oncolytic Virus Manufacturing and Development Services Revenue by Application in 2024
11.2.7 IDT Biologika Oncolytic Virus Manufacturing and Development Services Revenue by Geographic Area in 2024
11.2.8 IDT Biologika Oncolytic Virus Manufacturing and Development Services SWOT Analysis
11.2.9 IDT Biologika Recent Developments
11.3 FUJIFILM Diosynth Biotechnologies
11.3.1 FUJIFILM Diosynth Biotechnologies Corporation Information
11.3.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.3.3 FUJIFILM Diosynth Biotechnologies Oncolytic Virus Manufacturing and Development Services Product Features and Attributes
11.3.4 FUJIFILM Diosynth Biotechnologies Oncolytic Virus Manufacturing and Development Services Revenue and Gross Margin (2020-2025)
11.3.5 FUJIFILM Diosynth Biotechnologies Oncolytic Virus Manufacturing and Development Services Revenue by Product in 2024
11.3.6 FUJIFILM Diosynth Biotechnologies Oncolytic Virus Manufacturing and Development Services Revenue by Application in 2024
11.3.7 FUJIFILM Diosynth Biotechnologies Oncolytic Virus Manufacturing and Development Services Revenue by Geographic Area in 2024
11.3.8 FUJIFILM Diosynth Biotechnologies Oncolytic Virus Manufacturing and Development Services SWOT Analysis
11.3.9 FUJIFILM Diosynth Biotechnologies Recent Developments
11.4 Exothera
11.4.1 Exothera Corporation Information
11.4.2 Exothera Business Overview
11.4.3 Exothera Oncolytic Virus Manufacturing and Development Services Product Features and Attributes
11.4.4 Exothera Oncolytic Virus Manufacturing and Development Services Revenue and Gross Margin (2020-2025)
11.4.5 Exothera Oncolytic Virus Manufacturing and Development Services Revenue by Product in 2024
11.4.6 Exothera Oncolytic Virus Manufacturing and Development Services Revenue by Application in 2024
11.4.7 Exothera Oncolytic Virus Manufacturing and Development Services Revenue by Geographic Area in 2024
11.4.8 Exothera Oncolytic Virus Manufacturing and Development Services SWOT Analysis
11.4.9 Exothera Recent Developments
11.5 Lonza
11.5.1 Lonza Corporation Information
11.5.2 Lonza Business Overview
11.5.3 Lonza Oncolytic Virus Manufacturing and Development Services Product Features and Attributes
11.5.4 Lonza Oncolytic Virus Manufacturing and Development Services Revenue and Gross Margin (2020-2025)
11.5.5 Lonza Oncolytic Virus Manufacturing and Development Services Revenue by Product in 2024
11.5.6 Lonza Oncolytic Virus Manufacturing and Development Services Revenue by Application in 2024
11.5.7 Lonza Oncolytic Virus Manufacturing and Development Services Revenue by Geographic Area in 2024
11.5.8 Lonza Oncolytic Virus Manufacturing and Development Services SWOT Analysis
11.5.9 Lonza Recent Developments
11.6 Creative Biolabs
11.6.1 Creative Biolabs Corporation Information
11.6.2 Creative Biolabs Business Overview
11.6.3 Creative Biolabs Oncolytic Virus Manufacturing and Development Services Product Features and Attributes
11.6.4 Creative Biolabs Oncolytic Virus Manufacturing and Development Services Revenue and Gross Margin (2020-2025)
11.6.5 Creative Biolabs Recent Developments
11.7 Takara Bio
11.7.1 Takara Bio Corporation Information
11.7.2 Takara Bio Business Overview
11.7.3 Takara Bio Oncolytic Virus Manufacturing and Development Services Product Features and Attributes
11.7.4 Takara Bio Oncolytic Virus Manufacturing and Development Services Revenue and Gross Margin (2020-2025)
11.7.5 Takara Bio Recent Developments
11.8 Libentech
11.8.1 Libentech Corporation Information
11.8.2 Libentech Business Overview
11.8.3 Libentech Oncolytic Virus Manufacturing and Development Services Product Features and Attributes
11.8.4 Libentech Oncolytic Virus Manufacturing and Development Services Revenue and Gross Margin (2020-2025)
11.8.5 Libentech Recent Developments
11.9 ABL
11.9.1 ABL Corporation Information
11.9.2 ABL Business Overview
11.9.3 ABL Oncolytic Virus Manufacturing and Development Services Product Features and Attributes
11.9.4 ABL Oncolytic Virus Manufacturing and Development Services Revenue and Gross Margin (2020-2025)
11.9.5 ABL Recent Developments
11.10 Nabios
11.10.1 Nabios Corporation Information
11.10.2 Nabios Business Overview
11.10.3 Nabios Oncolytic Virus Manufacturing and Development Services Product Features and Attributes
11.10.4 Nabios Oncolytic Virus Manufacturing and Development Services Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Halix
11.11.1 Halix Corporation Information
11.11.2 Halix Business Overview
11.11.3 Halix Oncolytic Virus Manufacturing and Development Services Product Features and Attributes
11.11.4 Halix Oncolytic Virus Manufacturing and Development Services Revenue and Gross Margin (2020-2025)
11.11.5 Halix Recent Developments
11.12 Obio Technology
11.12.1 Obio Technology Corporation Information
11.12.2 Obio Technology Business Overview
11.12.3 Obio Technology Oncolytic Virus Manufacturing and Development Services Product Features and Attributes
11.12.4 Obio Technology Oncolytic Virus Manufacturing and Development Services Revenue and Gross Margin (2020-2025)
11.12.5 Obio Technology Recent Developments
11.13 Porton Advanced
11.13.1 Porton Advanced Corporation Information
11.13.2 Porton Advanced Business Overview
11.13.3 Porton Advanced Oncolytic Virus Manufacturing and Development Services Product Features and Attributes
11.13.4 Porton Advanced Oncolytic Virus Manufacturing and Development Services Revenue and Gross Margin (2020-2025)
11.13.5 Porton Advanced Recent Developments
11.14 WuXi ATU
11.14.1 WuXi ATU Corporation Information
11.14.2 WuXi ATU Business Overview
11.14.3 WuXi ATU Oncolytic Virus Manufacturing and Development Services Product Features and Attributes
11.14.4 WuXi ATU Oncolytic Virus Manufacturing and Development Services Revenue and Gross Margin (2020-2025)
11.14.5 WuXi ATU Recent Developments
11.15 Genevoyager
11.15.1 Genevoyager Corporation Information
11.15.2 Genevoyager Business Overview
11.15.3 Genevoyager Oncolytic Virus Manufacturing and Development Services Product Features and Attributes
11.15.4 Genevoyager Oncolytic Virus Manufacturing and Development Services Revenue and Gross Margin (2020-2025)
11.15.5 Genevoyager Recent Developments
12 Oncolytic Virus Manufacturing and Development ServicesIndustry Chain Analysis
12.1 Oncolytic Virus Manufacturing and Development Services Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Oncolytic Virus Manufacturing and Development Services Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Oncolytic Virus Manufacturing and Development Services Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to Oncolytic Virus Manufacturing and Development Services: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Oncolytic Virus Manufacturing and Development Services Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Oncolytic Herpes Simplex Virus
1.2.3 Oncolytic Adenovirus
1.2.4 Oncolytic Vaccinia Virus
1.2.5 Others
1.3 Market Segmentation by Application
1.3.1 Global Oncolytic Virus Manufacturing and Development Services Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 R&D
1.3.3 Biopharmaceutical Manufacturers
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Oncolytic Virus Manufacturing and Development Services Revenue Estimates and Forecasts 2020-2031
2.2 Global Oncolytic Virus Manufacturing and Development Services Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Oncolytic Virus Manufacturing and Development Services Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Oncolytic Virus Manufacturing and Development Services Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Oncolytic Herpes Simplex Virus Market Size by Players
3.3.2 Oncolytic Adenovirus Market Size by Players
3.3.3 Oncolytic Vaccinia Virus Market Size by Players
3.3.4 Others Market Size by Players
3.4 Global Oncolytic Virus Manufacturing and Development Services Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Oncolytic Virus Manufacturing and Development Services Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Oncolytic Virus Manufacturing and Development Services Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Oncolytic Virus Manufacturing and Development Services Market Size by Type (2020-2031)
6.4 North America Oncolytic Virus Manufacturing and Development Services Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Oncolytic Virus Manufacturing and Development Services Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Oncolytic Virus Manufacturing and Development Services Market Size by Type (2020-2031)
7.4 Europe Oncolytic Virus Manufacturing and Development Services Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Oncolytic Virus Manufacturing and Development Services Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Oncolytic Virus Manufacturing and Development Services Market Size by Type (2020-2031)
8.4 Asia-Pacific Oncolytic Virus Manufacturing and Development Services Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Oncolytic Virus Manufacturing and Development Services Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Oncolytic Virus Manufacturing and Development Services Market Size by Type (2020-2031)
9.4 Central and South America Oncolytic Virus Manufacturing and Development Services Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Oncolytic Virus Manufacturing and Development Services Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Oncolytic Virus Manufacturing and Development Services Market Size by Type (2020-2031)
10.4 Middle East and Africa Oncolytic Virus Manufacturing and Development Services Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Oncolytic Virus Manufacturing and Development Services Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Recipharm (Vibalogics)
11.1.1 Recipharm (Vibalogics) Corporation Information
11.1.2 Recipharm (Vibalogics) Business Overview
11.1.3 Recipharm (Vibalogics) Oncolytic Virus Manufacturing and Development Services Product Features and Attributes
11.1.4 Recipharm (Vibalogics) Oncolytic Virus Manufacturing and Development Services Revenue and Gross Margin (2020-2025)
11.1.5 Recipharm (Vibalogics) Oncolytic Virus Manufacturing and Development Services Revenue by Product in 2024
11.1.6 Recipharm (Vibalogics) Oncolytic Virus Manufacturing and Development Services Revenue by Application in 2024
11.1.7 Recipharm (Vibalogics) Oncolytic Virus Manufacturing and Development Services Revenue by Geographic Area in 2024
11.1.8 Recipharm (Vibalogics) Oncolytic Virus Manufacturing and Development Services SWOT Analysis
11.1.9 Recipharm (Vibalogics) Recent Developments
11.2 IDT Biologika
11.2.1 IDT Biologika Corporation Information
11.2.2 IDT Biologika Business Overview
11.2.3 IDT Biologika Oncolytic Virus Manufacturing and Development Services Product Features and Attributes
11.2.4 IDT Biologika Oncolytic Virus Manufacturing and Development Services Revenue and Gross Margin (2020-2025)
11.2.5 IDT Biologika Oncolytic Virus Manufacturing and Development Services Revenue by Product in 2024
11.2.6 IDT Biologika Oncolytic Virus Manufacturing and Development Services Revenue by Application in 2024
11.2.7 IDT Biologika Oncolytic Virus Manufacturing and Development Services Revenue by Geographic Area in 2024
11.2.8 IDT Biologika Oncolytic Virus Manufacturing and Development Services SWOT Analysis
11.2.9 IDT Biologika Recent Developments
11.3 FUJIFILM Diosynth Biotechnologies
11.3.1 FUJIFILM Diosynth Biotechnologies Corporation Information
11.3.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.3.3 FUJIFILM Diosynth Biotechnologies Oncolytic Virus Manufacturing and Development Services Product Features and Attributes
11.3.4 FUJIFILM Diosynth Biotechnologies Oncolytic Virus Manufacturing and Development Services Revenue and Gross Margin (2020-2025)
11.3.5 FUJIFILM Diosynth Biotechnologies Oncolytic Virus Manufacturing and Development Services Revenue by Product in 2024
11.3.6 FUJIFILM Diosynth Biotechnologies Oncolytic Virus Manufacturing and Development Services Revenue by Application in 2024
11.3.7 FUJIFILM Diosynth Biotechnologies Oncolytic Virus Manufacturing and Development Services Revenue by Geographic Area in 2024
11.3.8 FUJIFILM Diosynth Biotechnologies Oncolytic Virus Manufacturing and Development Services SWOT Analysis
11.3.9 FUJIFILM Diosynth Biotechnologies Recent Developments
11.4 Exothera
11.4.1 Exothera Corporation Information
11.4.2 Exothera Business Overview
11.4.3 Exothera Oncolytic Virus Manufacturing and Development Services Product Features and Attributes
11.4.4 Exothera Oncolytic Virus Manufacturing and Development Services Revenue and Gross Margin (2020-2025)
11.4.5 Exothera Oncolytic Virus Manufacturing and Development Services Revenue by Product in 2024
11.4.6 Exothera Oncolytic Virus Manufacturing and Development Services Revenue by Application in 2024
11.4.7 Exothera Oncolytic Virus Manufacturing and Development Services Revenue by Geographic Area in 2024
11.4.8 Exothera Oncolytic Virus Manufacturing and Development Services SWOT Analysis
11.4.9 Exothera Recent Developments
11.5 Lonza
11.5.1 Lonza Corporation Information
11.5.2 Lonza Business Overview
11.5.3 Lonza Oncolytic Virus Manufacturing and Development Services Product Features and Attributes
11.5.4 Lonza Oncolytic Virus Manufacturing and Development Services Revenue and Gross Margin (2020-2025)
11.5.5 Lonza Oncolytic Virus Manufacturing and Development Services Revenue by Product in 2024
11.5.6 Lonza Oncolytic Virus Manufacturing and Development Services Revenue by Application in 2024
11.5.7 Lonza Oncolytic Virus Manufacturing and Development Services Revenue by Geographic Area in 2024
11.5.8 Lonza Oncolytic Virus Manufacturing and Development Services SWOT Analysis
11.5.9 Lonza Recent Developments
11.6 Creative Biolabs
11.6.1 Creative Biolabs Corporation Information
11.6.2 Creative Biolabs Business Overview
11.6.3 Creative Biolabs Oncolytic Virus Manufacturing and Development Services Product Features and Attributes
11.6.4 Creative Biolabs Oncolytic Virus Manufacturing and Development Services Revenue and Gross Margin (2020-2025)
11.6.5 Creative Biolabs Recent Developments
11.7 Takara Bio
11.7.1 Takara Bio Corporation Information
11.7.2 Takara Bio Business Overview
11.7.3 Takara Bio Oncolytic Virus Manufacturing and Development Services Product Features and Attributes
11.7.4 Takara Bio Oncolytic Virus Manufacturing and Development Services Revenue and Gross Margin (2020-2025)
11.7.5 Takara Bio Recent Developments
11.8 Libentech
11.8.1 Libentech Corporation Information
11.8.2 Libentech Business Overview
11.8.3 Libentech Oncolytic Virus Manufacturing and Development Services Product Features and Attributes
11.8.4 Libentech Oncolytic Virus Manufacturing and Development Services Revenue and Gross Margin (2020-2025)
11.8.5 Libentech Recent Developments
11.9 ABL
11.9.1 ABL Corporation Information
11.9.2 ABL Business Overview
11.9.3 ABL Oncolytic Virus Manufacturing and Development Services Product Features and Attributes
11.9.4 ABL Oncolytic Virus Manufacturing and Development Services Revenue and Gross Margin (2020-2025)
11.9.5 ABL Recent Developments
11.10 Nabios
11.10.1 Nabios Corporation Information
11.10.2 Nabios Business Overview
11.10.3 Nabios Oncolytic Virus Manufacturing and Development Services Product Features and Attributes
11.10.4 Nabios Oncolytic Virus Manufacturing and Development Services Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Halix
11.11.1 Halix Corporation Information
11.11.2 Halix Business Overview
11.11.3 Halix Oncolytic Virus Manufacturing and Development Services Product Features and Attributes
11.11.4 Halix Oncolytic Virus Manufacturing and Development Services Revenue and Gross Margin (2020-2025)
11.11.5 Halix Recent Developments
11.12 Obio Technology
11.12.1 Obio Technology Corporation Information
11.12.2 Obio Technology Business Overview
11.12.3 Obio Technology Oncolytic Virus Manufacturing and Development Services Product Features and Attributes
11.12.4 Obio Technology Oncolytic Virus Manufacturing and Development Services Revenue and Gross Margin (2020-2025)
11.12.5 Obio Technology Recent Developments
11.13 Porton Advanced
11.13.1 Porton Advanced Corporation Information
11.13.2 Porton Advanced Business Overview
11.13.3 Porton Advanced Oncolytic Virus Manufacturing and Development Services Product Features and Attributes
11.13.4 Porton Advanced Oncolytic Virus Manufacturing and Development Services Revenue and Gross Margin (2020-2025)
11.13.5 Porton Advanced Recent Developments
11.14 WuXi ATU
11.14.1 WuXi ATU Corporation Information
11.14.2 WuXi ATU Business Overview
11.14.3 WuXi ATU Oncolytic Virus Manufacturing and Development Services Product Features and Attributes
11.14.4 WuXi ATU Oncolytic Virus Manufacturing and Development Services Revenue and Gross Margin (2020-2025)
11.14.5 WuXi ATU Recent Developments
11.15 Genevoyager
11.15.1 Genevoyager Corporation Information
11.15.2 Genevoyager Business Overview
11.15.3 Genevoyager Oncolytic Virus Manufacturing and Development Services Product Features and Attributes
11.15.4 Genevoyager Oncolytic Virus Manufacturing and Development Services Revenue and Gross Margin (2020-2025)
11.15.5 Genevoyager Recent Developments
12 Oncolytic Virus Manufacturing and Development ServicesIndustry Chain Analysis
12.1 Oncolytic Virus Manufacturing and Development Services Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Oncolytic Virus Manufacturing and Development Services Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Oncolytic Virus Manufacturing and Development Services Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Oncolytic Virus Manufacturing and Development Services Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Oncolytic Virus Manufacturing and Development Services Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Oncolytic Virus Manufacturing and Development Services Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Oncolytic Virus Manufacturing and Development Services Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Oncolytic Virus Manufacturing and Development Services Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Oncolytic Virus Manufacturing and Development Services Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Oncolytic Virus Manufacturing and Development Services Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Oncolytic Virus Manufacturing and Development Services by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus Manufacturing and Development Services as of 2024)
Table 11. Global Oncolytic Virus Manufacturing and Development Services Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Oncolytic Virus Manufacturing and Development Services Companies Headquarters
Table 13. Global Oncolytic Virus Manufacturing and Development Services Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Oncolytic Virus Manufacturing and Development Services Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Oncolytic Virus Manufacturing and Development Services Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Oncolytic Virus Manufacturing and Development Services Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Oncolytic Virus Manufacturing and Development Services Revenue by Application (2026-2031) & (US$ Million)
Table 21. Oncolytic Virus Manufacturing and Development Services High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Oncolytic Virus Manufacturing and Development Services Growth Accelerators and Market Barriers
Table 25. North America Oncolytic Virus Manufacturing and Development Services Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Oncolytic Virus Manufacturing and Development Services Growth Accelerators and Market Barriers
Table 27. Europe Oncolytic Virus Manufacturing and Development Services Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Oncolytic Virus Manufacturing and Development Services Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Oncolytic Virus Manufacturing and Development Services Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Oncolytic Virus Manufacturing and Development Services Investment Opportunities and Key Challenges
Table 31. Central and South America Oncolytic Virus Manufacturing and Development Services Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Oncolytic Virus Manufacturing and Development Services Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Oncolytic Virus Manufacturing and Development Services Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Recipharm (Vibalogics) Corporation Information
Table 35. Recipharm (Vibalogics) Description and Major Businesses
Table 36. Recipharm (Vibalogics) Product Features and Attributes
Table 37. Recipharm (Vibalogics) Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Recipharm (Vibalogics) Revenue Proportion by Product in 2024
Table 39. Recipharm (Vibalogics) Revenue Proportion by Application in 2024
Table 40. Recipharm (Vibalogics) Revenue Proportion by Geographic Area in 2024
Table 41. Recipharm (Vibalogics) Oncolytic Virus Manufacturing and Development Services SWOT Analysis
Table 42. Recipharm (Vibalogics) Recent Developments
Table 43. IDT Biologika Corporation Information
Table 44. IDT Biologika Description and Major Businesses
Table 45. IDT Biologika Product Features and Attributes
Table 46. IDT Biologika Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. IDT Biologika Revenue Proportion by Product in 2024
Table 48. IDT Biologika Revenue Proportion by Application in 2024
Table 49. IDT Biologika Revenue Proportion by Geographic Area in 2024
Table 50. IDT Biologika Oncolytic Virus Manufacturing and Development Services SWOT Analysis
Table 51. IDT Biologika Recent Developments
Table 52. FUJIFILM Diosynth Biotechnologies Corporation Information
Table 53. FUJIFILM Diosynth Biotechnologies Description and Major Businesses
Table 54. FUJIFILM Diosynth Biotechnologies Product Features and Attributes
Table 55. FUJIFILM Diosynth Biotechnologies Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. FUJIFILM Diosynth Biotechnologies Revenue Proportion by Product in 2024
Table 57. FUJIFILM Diosynth Biotechnologies Revenue Proportion by Application in 2024
Table 58. FUJIFILM Diosynth Biotechnologies Revenue Proportion by Geographic Area in 2024
Table 59. FUJIFILM Diosynth Biotechnologies Oncolytic Virus Manufacturing and Development Services SWOT Analysis
Table 60. FUJIFILM Diosynth Biotechnologies Recent Developments
Table 61. Exothera Corporation Information
Table 62. Exothera Description and Major Businesses
Table 63. Exothera Product Features and Attributes
Table 64. Exothera Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Exothera Revenue Proportion by Product in 2024
Table 66. Exothera Revenue Proportion by Application in 2024
Table 67. Exothera Revenue Proportion by Geographic Area in 2024
Table 68. Exothera Oncolytic Virus Manufacturing and Development Services SWOT Analysis
Table 69. Exothera Recent Developments
Table 70. Lonza Corporation Information
Table 71. Lonza Description and Major Businesses
Table 72. Lonza Product Features and Attributes
Table 73. Lonza Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Lonza Revenue Proportion by Product in 2024
Table 75. Lonza Revenue Proportion by Application in 2024
Table 76. Lonza Revenue Proportion by Geographic Area in 2024
Table 77. Lonza Oncolytic Virus Manufacturing and Development Services SWOT Analysis
Table 78. Lonza Recent Developments
Table 79. Creative Biolabs Corporation Information
Table 80. Creative Biolabs Description and Major Businesses
Table 81. Creative Biolabs Product Features and Attributes
Table 82. Creative Biolabs Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Creative Biolabs Recent Developments
Table 84. Takara Bio Corporation Information
Table 85. Takara Bio Description and Major Businesses
Table 86. Takara Bio Product Features and Attributes
Table 87. Takara Bio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Takara Bio Recent Developments
Table 89. Libentech Corporation Information
Table 90. Libentech Description and Major Businesses
Table 91. Libentech Product Features and Attributes
Table 92. Libentech Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Libentech Recent Developments
Table 94. ABL Corporation Information
Table 95. ABL Description and Major Businesses
Table 96. ABL Product Features and Attributes
Table 97. ABL Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. ABL Recent Developments
Table 99. Nabios Corporation Information
Table 100. Nabios Description and Major Businesses
Table 101. Nabios Product Features and Attributes
Table 102. Nabios Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Nabios Recent Developments
Table 104. Halix Corporation Information
Table 105. Halix Description and Major Businesses
Table 106. Halix Product Features and Attributes
Table 107. Halix Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Halix Recent Developments
Table 109. Obio Technology Corporation Information
Table 110. Obio Technology Description and Major Businesses
Table 111. Obio Technology Product Features and Attributes
Table 112. Obio Technology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Obio Technology Recent Developments
Table 114. Porton Advanced Corporation Information
Table 115. Porton Advanced Description and Major Businesses
Table 116. Porton Advanced Product Features and Attributes
Table 117. Porton Advanced Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Porton Advanced Recent Developments
Table 119. WuXi ATU Corporation Information
Table 120. WuXi ATU Description and Major Businesses
Table 121. WuXi ATU Product Features and Attributes
Table 122. WuXi ATU Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. WuXi ATU Recent Developments
Table 124. Genevoyager Corporation Information
Table 125. Genevoyager Description and Major Businesses
Table 126. Genevoyager Product Features and Attributes
Table 127. Genevoyager Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. Genevoyager Recent Developments
Table 129. Raw Materials Key Suppliers
Table 130. Distributors List
Table 131. Market Trends and Market Evolution
Table 132. Market Drivers and Opportunities
Table 133. Market Challenges, Risks, and Restraints
Table 134. Research Programs/Design for This Report
Table 135. Key Data Information from Secondary Sources
Table 136. Key Data Information from Primary Sources
List of Figures
Figure 1. Oncolytic Virus Manufacturing and Development Services Product Picture
Figure 2. Global Oncolytic Virus Manufacturing and Development Services Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Oncolytic Herpes Simplex Virus Product Picture
Figure 4. Oncolytic Adenovirus Product Picture
Figure 5. Oncolytic Vaccinia Virus Product Picture
Figure 6. Others Product Picture
Figure 7. Global Oncolytic Virus Manufacturing and Development Services Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. R&D
Figure 9. Biopharmaceutical Manufacturers
Figure 10. Others
Figure 11. Oncolytic Virus Manufacturing and Development Services Report Years Considered
Figure 12. Global Oncolytic Virus Manufacturing and Development Services Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 14. Global Oncolytic Virus Manufacturing and Development Services Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Oncolytic Virus Manufacturing and Development Services Revenue Market Share by Region (2020-2031)
Figure 16. Global Oncolytic Virus Manufacturing and Development Services Revenue Market Share Ranking (2024)
Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 18. Oncolytic Herpes Simplex Virus Revenue Market Share by Player in 2024
Figure 19. Oncolytic Adenovirus Revenue Market Share by Player in 2024
Figure 20. Oncolytic Vaccinia Virus Revenue Market Share by Player in 2024
Figure 21. Others Revenue Market Share by Player in 2024
Figure 22. Global Oncolytic Virus Manufacturing and Development Services Revenue Market Share by Type (2020-2031)
Figure 23. Global Oncolytic Virus Manufacturing and Development Services Revenue Market Share by Application (2020-2031)
Figure 24. North America Oncolytic Virus Manufacturing and Development Services Revenue YoY (2020-2031) & (US$ Million)
Figure 25. North America Top 5 Players Oncolytic Virus Manufacturing and Development Services Revenue (US$ Million) in 2024
Figure 26. North America Oncolytic Virus Manufacturing and Development Services Revenue (US$ Million) by Type (2020 - 2031)
Figure 27. North America Oncolytic Virus Manufacturing and Development Services Revenue (US$ Million) by Application (2020-2031)
Figure 28. US Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 29. Canada Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 30. Mexico Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 31. Europe Oncolytic Virus Manufacturing and Development Services Revenue YoY (2020-2031) & (US$ Million)
Figure 32. Europe Top 5 Players Oncolytic Virus Manufacturing and Development Services Revenue (US$ Million) in 2024
Figure 33. Europe Oncolytic Virus Manufacturing and Development Services Revenue (US$ Million) by Type (2020-2031)
Figure 34. Europe Oncolytic Virus Manufacturing and Development Services Revenue (US$ Million) by Application (2020-2031)
Figure 35. Germany Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 36. France Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 37. U.K. Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 38. Italy Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 39. Russia Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 40. Asia-Pacific Oncolytic Virus Manufacturing and Development Services Revenue YoY (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Top 8 Players Oncolytic Virus Manufacturing and Development Services Revenue (US$ Million) in 2024
Figure 42. Asia-Pacific Oncolytic Virus Manufacturing and Development Services Revenue (US$ Million) by Type (2020-2031)
Figure 43. Asia-Pacific Oncolytic Virus Manufacturing and Development Services Revenue (US$ Million) by Application (2020-2031)
Figure 44. Indonesia Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 45. Japan Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 46. South Korea Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 47. Australia Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 48. India Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 49. Indonesia Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 50. Vietnam Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 51. Malaysia Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 52. Philippines Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 53. Singapore Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 54. Central and South America Oncolytic Virus Manufacturing and Development Services Revenue YoY (2020-2031) & (US$ Million)
Figure 55. Central and South America Top 5 Players Oncolytic Virus Manufacturing and Development Services Revenue (US$ Million) in 2024
Figure 56. Central and South America Oncolytic Virus Manufacturing and Development Services Revenue (US$ Million) by Type (2020-2031)
Figure 57. Central and South America Oncolytic Virus Manufacturing and Development Services Revenue (US$ Million) by Application (2020-2031)
Figure 58. Brazil Oncolytic Virus Manufacturing and Development Services Revenue (2020-2025) & (US$ Million)
Figure 59. Argentina Oncolytic Virus Manufacturing and Development Services Revenue (2020-2025) & (US$ Million)
Figure 60. Middle East and Africa Oncolytic Virus Manufacturing and Development Services Revenue YoY (2020-2031) & (US$ Million)
Figure 61. Middle East and Africa Top 5 Players Oncolytic Virus Manufacturing and Development Services Revenue (US$ Million) in 2024
Figure 62. South America Oncolytic Virus Manufacturing and Development Services Revenue (US$ Million) by Type (2020-2031)
Figure 63. Middle East and Africa Oncolytic Virus Manufacturing and Development Services Revenue (US$ Million) by Application (2020-2031)
Figure 64. GCC Countries Oncolytic Virus Manufacturing and Development Services Revenue (2020-2025) & (US$ Million)
Figure 65. Israel Oncolytic Virus Manufacturing and Development Services Revenue (2020-2025) & (US$ Million)
Figure 66. Egypt Oncolytic Virus Manufacturing and Development Services Revenue (2020-2025) & (US$ Million)
Figure 67. South Africa Oncolytic Virus Manufacturing and Development Services Revenue (2020-2025) & (US$ Million)
Figure 68. Oncolytic Virus Manufacturing and Development Services Industry Chain Mapping
Figure 69. Channels of Distribution (Direct Vs Distribution)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
Table 1. Global Oncolytic Virus Manufacturing and Development Services Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Oncolytic Virus Manufacturing and Development Services Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Oncolytic Virus Manufacturing and Development Services Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Oncolytic Virus Manufacturing and Development Services Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Oncolytic Virus Manufacturing and Development Services Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Oncolytic Virus Manufacturing and Development Services Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Oncolytic Virus Manufacturing and Development Services Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Oncolytic Virus Manufacturing and Development Services by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus Manufacturing and Development Services as of 2024)
Table 11. Global Oncolytic Virus Manufacturing and Development Services Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Oncolytic Virus Manufacturing and Development Services Companies Headquarters
Table 13. Global Oncolytic Virus Manufacturing and Development Services Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Oncolytic Virus Manufacturing and Development Services Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Oncolytic Virus Manufacturing and Development Services Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Oncolytic Virus Manufacturing and Development Services Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Oncolytic Virus Manufacturing and Development Services Revenue by Application (2026-2031) & (US$ Million)
Table 21. Oncolytic Virus Manufacturing and Development Services High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Oncolytic Virus Manufacturing and Development Services Growth Accelerators and Market Barriers
Table 25. North America Oncolytic Virus Manufacturing and Development Services Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Oncolytic Virus Manufacturing and Development Services Growth Accelerators and Market Barriers
Table 27. Europe Oncolytic Virus Manufacturing and Development Services Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Oncolytic Virus Manufacturing and Development Services Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Oncolytic Virus Manufacturing and Development Services Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Oncolytic Virus Manufacturing and Development Services Investment Opportunities and Key Challenges
Table 31. Central and South America Oncolytic Virus Manufacturing and Development Services Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Oncolytic Virus Manufacturing and Development Services Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Oncolytic Virus Manufacturing and Development Services Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Recipharm (Vibalogics) Corporation Information
Table 35. Recipharm (Vibalogics) Description and Major Businesses
Table 36. Recipharm (Vibalogics) Product Features and Attributes
Table 37. Recipharm (Vibalogics) Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Recipharm (Vibalogics) Revenue Proportion by Product in 2024
Table 39. Recipharm (Vibalogics) Revenue Proportion by Application in 2024
Table 40. Recipharm (Vibalogics) Revenue Proportion by Geographic Area in 2024
Table 41. Recipharm (Vibalogics) Oncolytic Virus Manufacturing and Development Services SWOT Analysis
Table 42. Recipharm (Vibalogics) Recent Developments
Table 43. IDT Biologika Corporation Information
Table 44. IDT Biologika Description and Major Businesses
Table 45. IDT Biologika Product Features and Attributes
Table 46. IDT Biologika Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. IDT Biologika Revenue Proportion by Product in 2024
Table 48. IDT Biologika Revenue Proportion by Application in 2024
Table 49. IDT Biologika Revenue Proportion by Geographic Area in 2024
Table 50. IDT Biologika Oncolytic Virus Manufacturing and Development Services SWOT Analysis
Table 51. IDT Biologika Recent Developments
Table 52. FUJIFILM Diosynth Biotechnologies Corporation Information
Table 53. FUJIFILM Diosynth Biotechnologies Description and Major Businesses
Table 54. FUJIFILM Diosynth Biotechnologies Product Features and Attributes
Table 55. FUJIFILM Diosynth Biotechnologies Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. FUJIFILM Diosynth Biotechnologies Revenue Proportion by Product in 2024
Table 57. FUJIFILM Diosynth Biotechnologies Revenue Proportion by Application in 2024
Table 58. FUJIFILM Diosynth Biotechnologies Revenue Proportion by Geographic Area in 2024
Table 59. FUJIFILM Diosynth Biotechnologies Oncolytic Virus Manufacturing and Development Services SWOT Analysis
Table 60. FUJIFILM Diosynth Biotechnologies Recent Developments
Table 61. Exothera Corporation Information
Table 62. Exothera Description and Major Businesses
Table 63. Exothera Product Features and Attributes
Table 64. Exothera Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Exothera Revenue Proportion by Product in 2024
Table 66. Exothera Revenue Proportion by Application in 2024
Table 67. Exothera Revenue Proportion by Geographic Area in 2024
Table 68. Exothera Oncolytic Virus Manufacturing and Development Services SWOT Analysis
Table 69. Exothera Recent Developments
Table 70. Lonza Corporation Information
Table 71. Lonza Description and Major Businesses
Table 72. Lonza Product Features and Attributes
Table 73. Lonza Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Lonza Revenue Proportion by Product in 2024
Table 75. Lonza Revenue Proportion by Application in 2024
Table 76. Lonza Revenue Proportion by Geographic Area in 2024
Table 77. Lonza Oncolytic Virus Manufacturing and Development Services SWOT Analysis
Table 78. Lonza Recent Developments
Table 79. Creative Biolabs Corporation Information
Table 80. Creative Biolabs Description and Major Businesses
Table 81. Creative Biolabs Product Features and Attributes
Table 82. Creative Biolabs Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Creative Biolabs Recent Developments
Table 84. Takara Bio Corporation Information
Table 85. Takara Bio Description and Major Businesses
Table 86. Takara Bio Product Features and Attributes
Table 87. Takara Bio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Takara Bio Recent Developments
Table 89. Libentech Corporation Information
Table 90. Libentech Description and Major Businesses
Table 91. Libentech Product Features and Attributes
Table 92. Libentech Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Libentech Recent Developments
Table 94. ABL Corporation Information
Table 95. ABL Description and Major Businesses
Table 96. ABL Product Features and Attributes
Table 97. ABL Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. ABL Recent Developments
Table 99. Nabios Corporation Information
Table 100. Nabios Description and Major Businesses
Table 101. Nabios Product Features and Attributes
Table 102. Nabios Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Nabios Recent Developments
Table 104. Halix Corporation Information
Table 105. Halix Description and Major Businesses
Table 106. Halix Product Features and Attributes
Table 107. Halix Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Halix Recent Developments
Table 109. Obio Technology Corporation Information
Table 110. Obio Technology Description and Major Businesses
Table 111. Obio Technology Product Features and Attributes
Table 112. Obio Technology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Obio Technology Recent Developments
Table 114. Porton Advanced Corporation Information
Table 115. Porton Advanced Description and Major Businesses
Table 116. Porton Advanced Product Features and Attributes
Table 117. Porton Advanced Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Porton Advanced Recent Developments
Table 119. WuXi ATU Corporation Information
Table 120. WuXi ATU Description and Major Businesses
Table 121. WuXi ATU Product Features and Attributes
Table 122. WuXi ATU Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. WuXi ATU Recent Developments
Table 124. Genevoyager Corporation Information
Table 125. Genevoyager Description and Major Businesses
Table 126. Genevoyager Product Features and Attributes
Table 127. Genevoyager Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. Genevoyager Recent Developments
Table 129. Raw Materials Key Suppliers
Table 130. Distributors List
Table 131. Market Trends and Market Evolution
Table 132. Market Drivers and Opportunities
Table 133. Market Challenges, Risks, and Restraints
Table 134. Research Programs/Design for This Report
Table 135. Key Data Information from Secondary Sources
Table 136. Key Data Information from Primary Sources
List of Figures
Figure 1. Oncolytic Virus Manufacturing and Development Services Product Picture
Figure 2. Global Oncolytic Virus Manufacturing and Development Services Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Oncolytic Herpes Simplex Virus Product Picture
Figure 4. Oncolytic Adenovirus Product Picture
Figure 5. Oncolytic Vaccinia Virus Product Picture
Figure 6. Others Product Picture
Figure 7. Global Oncolytic Virus Manufacturing and Development Services Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. R&D
Figure 9. Biopharmaceutical Manufacturers
Figure 10. Others
Figure 11. Oncolytic Virus Manufacturing and Development Services Report Years Considered
Figure 12. Global Oncolytic Virus Manufacturing and Development Services Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 14. Global Oncolytic Virus Manufacturing and Development Services Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Oncolytic Virus Manufacturing and Development Services Revenue Market Share by Region (2020-2031)
Figure 16. Global Oncolytic Virus Manufacturing and Development Services Revenue Market Share Ranking (2024)
Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 18. Oncolytic Herpes Simplex Virus Revenue Market Share by Player in 2024
Figure 19. Oncolytic Adenovirus Revenue Market Share by Player in 2024
Figure 20. Oncolytic Vaccinia Virus Revenue Market Share by Player in 2024
Figure 21. Others Revenue Market Share by Player in 2024
Figure 22. Global Oncolytic Virus Manufacturing and Development Services Revenue Market Share by Type (2020-2031)
Figure 23. Global Oncolytic Virus Manufacturing and Development Services Revenue Market Share by Application (2020-2031)
Figure 24. North America Oncolytic Virus Manufacturing and Development Services Revenue YoY (2020-2031) & (US$ Million)
Figure 25. North America Top 5 Players Oncolytic Virus Manufacturing and Development Services Revenue (US$ Million) in 2024
Figure 26. North America Oncolytic Virus Manufacturing and Development Services Revenue (US$ Million) by Type (2020 - 2031)
Figure 27. North America Oncolytic Virus Manufacturing and Development Services Revenue (US$ Million) by Application (2020-2031)
Figure 28. US Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 29. Canada Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 30. Mexico Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 31. Europe Oncolytic Virus Manufacturing and Development Services Revenue YoY (2020-2031) & (US$ Million)
Figure 32. Europe Top 5 Players Oncolytic Virus Manufacturing and Development Services Revenue (US$ Million) in 2024
Figure 33. Europe Oncolytic Virus Manufacturing and Development Services Revenue (US$ Million) by Type (2020-2031)
Figure 34. Europe Oncolytic Virus Manufacturing and Development Services Revenue (US$ Million) by Application (2020-2031)
Figure 35. Germany Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 36. France Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 37. U.K. Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 38. Italy Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 39. Russia Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 40. Asia-Pacific Oncolytic Virus Manufacturing and Development Services Revenue YoY (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Top 8 Players Oncolytic Virus Manufacturing and Development Services Revenue (US$ Million) in 2024
Figure 42. Asia-Pacific Oncolytic Virus Manufacturing and Development Services Revenue (US$ Million) by Type (2020-2031)
Figure 43. Asia-Pacific Oncolytic Virus Manufacturing and Development Services Revenue (US$ Million) by Application (2020-2031)
Figure 44. Indonesia Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 45. Japan Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 46. South Korea Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 47. Australia Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 48. India Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 49. Indonesia Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 50. Vietnam Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 51. Malaysia Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 52. Philippines Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 53. Singapore Oncolytic Virus Manufacturing and Development Services Revenue (2020-2031) & (US$ Million)
Figure 54. Central and South America Oncolytic Virus Manufacturing and Development Services Revenue YoY (2020-2031) & (US$ Million)
Figure 55. Central and South America Top 5 Players Oncolytic Virus Manufacturing and Development Services Revenue (US$ Million) in 2024
Figure 56. Central and South America Oncolytic Virus Manufacturing and Development Services Revenue (US$ Million) by Type (2020-2031)
Figure 57. Central and South America Oncolytic Virus Manufacturing and Development Services Revenue (US$ Million) by Application (2020-2031)
Figure 58. Brazil Oncolytic Virus Manufacturing and Development Services Revenue (2020-2025) & (US$ Million)
Figure 59. Argentina Oncolytic Virus Manufacturing and Development Services Revenue (2020-2025) & (US$ Million)
Figure 60. Middle East and Africa Oncolytic Virus Manufacturing and Development Services Revenue YoY (2020-2031) & (US$ Million)
Figure 61. Middle East and Africa Top 5 Players Oncolytic Virus Manufacturing and Development Services Revenue (US$ Million) in 2024
Figure 62. South America Oncolytic Virus Manufacturing and Development Services Revenue (US$ Million) by Type (2020-2031)
Figure 63. Middle East and Africa Oncolytic Virus Manufacturing and Development Services Revenue (US$ Million) by Application (2020-2031)
Figure 64. GCC Countries Oncolytic Virus Manufacturing and Development Services Revenue (2020-2025) & (US$ Million)
Figure 65. Israel Oncolytic Virus Manufacturing and Development Services Revenue (2020-2025) & (US$ Million)
Figure 66. Egypt Oncolytic Virus Manufacturing and Development Services Revenue (2020-2025) & (US$ Million)
Figure 67. South Africa Oncolytic Virus Manufacturing and Development Services Revenue (2020-2025) & (US$ Million)
Figure 68. Oncolytic Virus Manufacturing and Development Services Industry Chain Mapping
Figure 69. Channels of Distribution (Direct Vs Distribution)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Motor Brush Rocker Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 16, 25
Global Pediatric Mandibular Distractor System Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 16, 25
Global Automatic Coercive Force Meter Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 16, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232